Zai Lab (ZLAB) Stock Price, News & Analysis

Company Overview

Zai Lab Limited is a biopharmaceutical company focused on discovering, developing and commercializing medicines for significant unmet medical needs. The company’s research and development activities have centered on oncology, autoimmune and inflammatory diseases, infectious diseases, and neuroscience. Zai Lab operates through a combination of internally developed programs and collaborations with global pharmaceutical and biotechnology companies.

The company has built a commercial portfolio in Greater China that has included ZEJULA (niraparib), a PARP inhibitor used in certain ovarian cancer settings; QINLOCK (ripretinib), a treatment for gastrointestinal stromal tumors; and NUZYRA (omadacycline), an antibiotic for certain bacterial infections. Zai Lab has also advanced and commercialized additional partnered therapies in China and maintains a pipeline of investigational medicines across its core therapeutic areas.

Founded in 2014, Zai Lab is headquartered in Shanghai and has operations in China, the United States and other international markets. The company was founded by Samantha Du, who has served as its chief executive officer and has led its strategy of developing a globally oriented biopharmaceutical business with a focus on bringing innovative treatments to patients in China and other regions.

Key Stats

• Today's Range: $23.89 to $24.56
• 50-Day Range: $18.18 to $27.00
• 52-Week Range: $15.96 to $34.72
• Volume: 737,184 shs
• Average Volume: 862,739 shs
• Market Capitalization: $2.80 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Moderate Buy

Zai Lab Stock Analysis - MarketRank™

Zai Lab scored higher than 46% of companies evaluated by MarketBeat, and ranked 602nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Zai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Zai Lab has a consensus price target of $37.25, representing about 53.3% upside from its current price of $24.30.

Amount of Analyst Coverage

Zai Lab has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Zai Lab are expected to grow in the coming year, from ($2.37) to ($2.36) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Zai Lab is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Zai Lab is -14.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Zai Lab has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.41% of the float of Zai Lab has been sold short.

Short Interest Ratio / Days to Cover

Zai Lab has a short interest ratio ("days to cover") of 7.33.

Change versus previous month

Short interest in Zai Lab has recently increased by 7.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Zai Lab does not currently pay a dividend.

Dividend Growth

Zai Lab does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.71

News Sentiment

Zai Lab has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Zai Lab this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $960,741.00 in company stock.

Percentage Held by Insiders

4.88% of the stock of Zai Lab is held by insiders.

Percentage Held by Institutions

41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ZLAB
• CIK: 1704292
• Web: www.zailaboratory.com
• Phone: 862161632588
• Fax: 86-21-6163-2570
• Employees: 1,784
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Zai Lab: $37.25
• High Price Target: $45.00
• Low Price Target: $32.00
• Potential Upside/Downside: +51.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$175.54 million
• Net Margins: -41.86%
• Pretax Margin: -42.42%
• Return on Equity: -27.43%
• Return on Assets: -16.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.13
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $449.61 million
• Price / Sales: 6.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.39 per share
• Price / Book: 3.84

Miscellaneous

• Outstanding Shares: 113,783,000
• Free Float: 108,230,000
• Market Cap: $2.79 billion
• Optionable: Optionable
• Beta: 0.83